Dosimertinib (mesylate)

Dosimertinib (mesylate)

• CAS Number: 2403760-72-3
• UNSPSC Description: Dosimertinib-d5 (mesylate) is a potent and orally active EGFR inhibitor. Dosimertinib-d5 (mesylate) decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d5 (mesylate) shows antiproliferative and anti-tumor activity. Dosimertinib-d5 (mesylate) has the potential for the research of non-small-cell lung cancer (NSCLC)[1].
• Target Antigen: EGFR
• Type: Isotope-Labeled Compounds
• Related Pathways: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Solubility: DMSO : 100 mg/mL (ultrasonic;warming;heat to 80°C)
• Smiles: CS(=O)(O)=O.[2H]/C([2H])=C\C(NC1=CC(NC2=NC=CC(C3=CN(C4=C3C=CC=C4)C([2H])([2H])[2H])=N2)=C(C=C1N(CCN(C)C)C)OC)=O
• Molecular Weight: 600.74
• References & Citations: [1]Meng Y, et al. Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer. J Med Chem. 2021 Jan 28;64(2):925-937.
• Shipping Conditions: Blue Ice
• Clinical Information: No Development Reported